Oncolytics Biotech announced that it has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer, or NSCLC, with Kras or EGFR-activated tumours. This trial is a single arm, single-stage, open-label, Phase 2 study of Reolysin given intravenously with paclitaxel and carboplatin every three weeks. Patients received four to six cycles of paclitaxel and carboplatin in conjunction with Reolysin, following which Reolysin could be continued as a monotherapy. Eligible patients included those with metastatic or recurrent NSCLC with Kras or EGFR-activated tumours, who had not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in Kras or EGFR, or EGFR gene amplification in their tumours, metastatic or primary, in order to qualify for the trial.